Aromatherapy Carrier Oils Market Size Worth $1.9 Billion By 2026

The global aromatherapy carrier oil market is expected to account for USD 1.90 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 10%. Growing awareness and increasing use of therapeutic carrier oils has led to high market growth. Aromatherapy is considered an alternative to medicinal therapy for treatment of a wide range of conditions. Thus, with growing awareness about the field of alternative & complementary medicine, therapeutic-grade carrier oils are increasingly being adopted due to their healing properties.

In addition, adoption of natural products has increased as a number of adverse effects are associated with pharmaceutical products. For instance, apricot kernel oil is widely used for skin & hair care and scar & pain management as well as in manufacturing of soaps.

Aromatherapy products such as carrier oils have also been proven to be highly effective in pain management and healing of wounds & cuts. These products consist of healing as well as antibacterial properties.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/aromatherapy-carrier-oil-market

Further key findings from the study suggest:

Cosmetics segment dominated the aromatherapy carrier oils market in 2018 and is anticipated to grow at a lucrative rate during the forecast period owing to increase in incidence of skin and hair problems
Medical segment also held significant share in 2018 owing to growing awareness about the various types of therapeutic-grade products available
Rapid industrialization and increasing consumer awareness regarding new medical practices have led to an increase in demand for these products globally
In 2018, personal care segment was expected to witness lucrative CAGR over the forecast period owing to increase in use of carrier oils as a base for manufacturing soaps
North America held the largest market share in 2018 owing to rise in the number of key players introducing therapeutic grade products in the U.S.
Lucrative trading opportunities have led to an increase in growth potential of the European market
Asia Pacific is projected to exhibit significant growth rate over the forecast period due to growing awareness pertaining to aromatherapy as well as rise in incidence of skin disorders in this region
Some of the key companies are Edens Garden, Rocky Mountain Oils, Plant Therapy Essential Oils, Falcon Essential Oils, FLORIHANA, and Moksha Lifestyle Products

Cold Pain Therapy Market Size Worth $2.3 Billion By 2026

The global cold pain therapy market size is expected to reach USD 2.3 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 4.9%. Rising incidence of orthopedic diseases has led to high growth of the market. CDC estimated that nearly 78 million people in the U.S., aged 18 years or above, are expected to be diagnosed with arthritis by 2040.

Rising number of road accidents and traumatic injuries is leading to a high growth of the market. According to WHO data, every year nearly 10 million people suffer injuries in road accidents or incur a disability as a result of injuries in head, chest, arms, and legs. Thus, with the increasing number of road accidents, the demand for therapy products for pain management is rising. Increasing number of sports injuries also play a pivotal role in the rising demand for these products. The most common types of sport injuries are dislocated joints, muscle sprains & strains, tear of ligaments & tendons that hold the joints together, and fractured bones, including the vertebrae.

Geriatric population is a significant target population driving the market. Countries such as Germany and China have high geriatric population base. This factor is contributing to market growth. According to CDC, 1 in every 4 adults are affected by osteoarthritis. Thus, rising geriatric population is expected to increase the demand for cold pain therapy products.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/cold-pain-therapy-market

Further key findings from the report suggest:

OTC products dominated the market in 2018 due to affordability and easy availability of products such as creams, gels, sprays, and roll-ons
Orthopedic conditions held a significant market share in 2018 owing to rising prevalence of various musculoskeletal and joint disorders, such as osteoarthritis
The sports medicine segment is expected to witness a significant growth during the forecast period due to increasing number of sport-related injuries
Retail pharmacies accounted for a considerable revenue share in 2018, owing to increase in their demand due to easy availability of products
Among all distribution channels, e-commerce is expected to grow at the highest CAGR during the forecast period, owing to lucrative offers and discounts available online
North America dominated the cold pain therapy market in 2018 due to factors such as an increase in the prevalence of orthopedic disorders and presence of key market players in the region
Asia Pacific is likely to grow at a high rate over the forecast period due to rising geriatric population, coupled with growing healthcare awareness in the region
Some of the major companies in the market are Beiersdorf; Breg, Inc.; DJO Global; Hisamitsu Pharmaceutical Co., Inc.; Johnson & Johnson; and Össur Corporate.

Industrial Bulk Packaging Market Worth $28.4 Billion By 2025

The global industrial bulk packaging market size is projected to reach USD 28.4 billion by 2025, escalating at a CAGR of 3.8% over the forecast period, according to a new report by Grand View Research, Inc. Bulk packaging products are expected to witness high penetration in the chemicals & petrochemicals sector over the forecast period. Industrial bulk packaging solutions have witnessed increased demand in the recent years owing to rising global industrial output, most notably in Asia Pacific.

The rising demand for reducing the cost of transportation and storage of industrial fluids across industries is another factor bolstering the consumption of industrial bulk packaging products. In this regard, products such as IBCs and pails are increasingly consumed to ensure optimal space utilization, thereby contributing favorably to industry growth. The industry is also driven by steps initiated by various governments around the world to increase domestic production of petrochemicals.

The Government of India (GoI) recently initiated a perspective planning concerning the petrochemical industry to boost domestic capacities (petrochemicals) as a part of its Petroleum, Chemicals and Petrochemicals Investment Region (PCPIR) policy. Such initiatives offer healthy prospects for industry growth. In terms of application, chemicals & petrochemicals segment emerged as the largest segment in 2018, holding a share of 40.1%

Pharmaceuticals segment is poised to register the fastest growth rate over the forecast period with the rising need for product safety (pharmaceuticals) coupled with advancements in scientific stacking methods (bulk packaging). Furthermore, increasing focus on the reduction of pharmaceutical wastage both during loading and unloading necessitates the employment of bulk packing products. The presence of aging population in Europe has been creating a substantial demand for industrial bulk packaging products in the pharmaceuticals space in the region.

North America emerged as one of the prominent regions for industrial bulk packaging. The U.S. was observed to be the most prominent market in North America and is characterized by the presence of leading international industry players. Furthermore, the North American market has been witnessing an increasing adoption of novel packaging products including flexible IBCs over the years. Such factors are expected to strengthen the regional market in the near future.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/industrial-bulk-packaging-market

Further key findings from the report suggest:

In terms of product, the drums segment dominated the industrial bulk packaging market with a share of 40.6% in 2018; however, the segment is expected to lose share to segments such as IBCs and pails owing to the increasing demand for smaller formats of industrial bulk packing solutions
Europe was the second-largest market for industrial bulk packaging in 2018
The industry is characterized by intense competition with both domestic and international players trying to target prospective clients
Product differentiation and innovation were some of the preferred strategies deployed by key market players.

Scleroderma Therapeutics Market Size Worth $2.6 Billion By 2026

The global scleroderma therapeutics market size is expected to reach over USD 2.6 billion by 2026 registering a CAGR of 6.0%, according to a new study by Grand View Research, Inc. The market growth is credited to the availability of various therapies used off-label, such as small molecule therapies including branded, generics, and OTC drugs.

The mix of several indications and drug classes engenders a fragmented market with multiple players. Roche is the dominant company with biologic immunosuppressants, Actemra/RoActemra, Cellcept, and Rituxan contributing majorly to the company’s share. Pfizer and Eli Lilly are the key companies in the market. Over the forecast period, new entrants including Boehringer Ingelheim, Corbus Pharmaceuticals, and Fibrocell will marginally displace the share of established firms in this market.

The on-label market is in the development phase. Supplemental indication approval is one of the most common strategies adopted by market participants. For example, riociguat by Bayer was previously used for PAH and currently, it is under clinical trials for the treatment of SSc-related digital ulcers. There are several other pharmaceutical companies following suit as this strategy favors the pharmaceutical industry in offsetting high development costs and in reaping larger benefits from one molecule already developed and present in the market.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/scleroderma-therapeutics-market

Further key findings from the study suggest:

The immunosuppressants segment held the largest market share in 2018 and is likely to maintain the dominance throughout the forecast years
High preference for immunosuppressants owing to the favorable reimbursement scenario associated with this drug class supports its dominant market share
Systemic scleroderma indication segment accounted for the major market share and will expand further due to use of high-priced immunosuppressants
U.S. held the majority of the share in 2018. Expected label expansions and expected launch of first-in-class therapies coupled with an evolving reimbursement landscape for orphan drugs support continual scleroderma therapeutics market growth
Europe trails with a lower share as compared to the U.S. majorly due to higher use of generics and biosimilars for off-label treatment of scleroderma
Some of the key companies are F. Hoffman La-Roche Ltd.; Bristol-Myers Squibb Company; Celgene Corp.; arGentis Pharmaceuticals, LLC; Bayer AG; Boehringer Ingelheim International GmbH; Akashi Therapeutics; Prometic Life Sciences, Inc.; Emerald Health Pharmaceuticals; Kadmon Holdings, Inc.; Seattle Genetics, Inc.; Cytori Therapeutics, Inc.; Fibrocell Science, Inc.; Chemomab; Corbus Pharmaceuticals Holdings, Inc.; and Genkyotex SA

Interleukin Inhibitors Market Worth $74.6 Billion By 2026

The global interleukin inhibitors market size is expected to reach USD 74.6 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 17.4% over the forecast period. This can be attributed to a strong pipeline with upcoming launches of late-stage pipeline drugs.

The therapeutic landscape in this market is becoming increasingly competitive, as drugs are compared in head-to-head trials to determine superiority in terms of safety, efficacy, and tolerance. For instance, UCB’s bimekizumab is currently under investigation in three such trials against Humira (trial name: BE SURE), Stelara (BE VIVID), and Cosentyx (BE RADIANT)-indicated for plaque psoriasis.

Furthermore, increasing investments on various clinical trials and strategic alliances between pharmaceutical companies and research organizations for development of novel molecules are few major contributors to interleukin inhibitors market growth. For instance, Genentech (F. Hoffmann-La Roche Ltd.) has collaborated with Massachusetts General Hospital for developing Actemra (tocilizumab) for the treatment of giant cell arteritis.

Rise in consumer awareness about various autoimmune diseases and their treatment options is anticipated to impel demand. For instance, Arthritis Ireland launched an awareness campaign for rheumatoid arthritis, educating the public about different treatment options and significance of early diagnosis. In addition, the European Federation of Crohn’s & Ulcerative Colitis Association offers various initiatives to create awareness among patients suffering from Inflammatory Bowel Disease (IBD).

Click the link below:
https://www.grandviewresearch.com/industry-analysis/interleukin-inhibitors-market

Further key findings from the report suggest:

Psoriatic arthritis and IBD are projected to register fastest growth through to 2026
IL-17 is likely to overtake IL-23 as the leading type by 2026
IL-5 inhibitors for asthma to witness strong growth in the near future
Asia Pacific is expected to exhibit the fastest regional growth
Despite the high price of IL-inhibitors, favorable reimbursement policies are likely to provide affordability and support market penetration

Quillaia Extract Market Size Worth $1.05 Billion By 2025

The global quillaia extracts market size is anticipated to reach USD 1.05 billion by 2025, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 5.2% over the forecast period. Increasing consumption of natural ingredients, changing food habits, and wide range of applications of the product in industries such as food and beverage, medical, and personal care among others are anticipated to drive the growth.

Quillaia extract is largely used for manufacturing cream soda, cider, puddings, baked goods, and frozen dairy products among other food and beverages. The extract is used in different quantities in different products. For instance, in carbonated beverages, the concentration of quillaia extract is upto 200mg/kg wherein in noncarbonated drinks, it is used upto 500mg/kg. Food and beverage held the largest market share of 36.45% in 2018, owing to the rising demand for foam stabilizing agents. The product is water soluble foaming compound that helps maintain temperature, taste, and shelf stability, which drive the application.

Increasing demand for organic and natural skincare products is anticipated to bode well for the quillaia extract market. One of the market players, Desert King offers different types of quillaia extract, namely, Andean Pure Quillaia, Andean Q Ultra, Andean Q Ultra Organic, Andean QDP Ultra Organic, Andean QE, and Andean QD for cosmetic application.

Liquid quillaia product type is anticipated to expand at a CAGR of 5.3% over the forecast period. The liquid extract is smooth and textureless making it suitable for curries and sauces. It is widely used as a foaming agent in soft drinks such as ginger beer, root beer, and cream soda, and in cocktails among other drinks. It has sweet and pungent smell and turns into foam upon shaking, hence it finds application in personal care application. For instance, Puracy, uses liquid quillaia extract in its natural conditioners, shampoos, and skin care products.

Asia Pacific held the largest market share of over 32% in 2018, due to high product consumption in Australia and New Zealand. According to a report by the Bureau of Chemical Safety, the mean quillaia extract intake in Australia was 2.3mg/kg per day and 1.1 mg/kg per day in New Zealand. The quillaia extract is also known as China bark extract, as the quillaia trees are native to China. The product is widely used in food products like soy sauce. High demand for organic and natural cosmetics in India, China, and Japan will boost the regional growth.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/quillaia-extracts-market

Further key findings from the report suggest:

Food and beverage segment held the largest market share of 36.45% in 2018 and is anticipated to continue leading during the forecast period
Liquid product type is anticipated to expand at a CAGR of 5.4% over the forecast period
Asia Pacific held the largest share of the global quillaia extract market in 2018
Leading market players are Garuda International, Naturex, Ingredion, Stan Chem International, Desert King, Baja Yucca, and Chile Botanics among others

Lymphoma Treatment Market Size Worth $26.4 Billion By 2026

The global lymphoma treatment market size is expected to reach USD 26.4 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 9.5%. Rising research activities for development of new treatments and increasing product line extension are likely to expedite growth. Increasing commercialization of novel drugs are further expected to drive the growth.

Availability of wide variety of products is further expected to aid growth. For instance, in January 2019, BeiGene received a breakthrough therapy designation by the U.S. FDA for its product Zanubrutinib for treating mantle cell lymphoma in adults. This drug is currently in late-stage clinical trial and is expected to be launched during the forecast period.

Growing awareness about early diagnosis of lymphoma among healthcare professionals & patients and rising government funding for R&D are some factors expected to propel market growth. For instance, institutes such as National Cancer Institute receives funding from the U.S. Congress to support cancer-related research and associated activities.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/lymphoma-market

Further key findings from the report suggest:

Non-Hodgkin lymphoma held the largest share in 2018 owing to prevalence of non-Hodgkin lymphoma and presence of blockbuster drugs.
Hodgkin lymphoma is expected to be the fastest growing segment due to presence of strong product pipeline and increase in the number of label extension for existing drugs.
Based on drug, Revlimid held the highest share in 2018 and is expected to grow at a significant rate during the forecast period. This can be attributed to growing use of this product in cancer treatment regimens.
Rituxan/MabThera held the second largest share in 2018 owing to increasing use of this product in multiple indications and high prescription rate in major markets such as the U.S., Europe, and Japan.
North America dominated in 2018, followed by Europe. This can be attributed to well-established healthcare infrastructure, high R&D expenditure, availability of novel drugs, and presence of key players.
Asia Pacific is expected to be the fastest growing over the forecast period owing to increase in commercialization of products, rise in awareness about diseases and high unmet clinical needs.
Some of the major players are Celgene Corporation; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd.; Seattle Genetics, Inc.; Merck & Co., Inc.; Johnson & Johnson; Takeda Pharmaceutical Company Ltd.; Abbott Laboratories; and Eli Lilly and Company.
Key players for lymphoma treatment market are adopting strategies such as collaborations, mergers & acquisitions, product development, product line extension, and regional expansion to increase their share. For instance, Seattle Genetics collaborated with Takeda Pharmaceuticals for commercialization of Adcetris in different regions other than North America.

Anti-infective Agents Market Worth $144.8 Billion By 2026

The global anti-infective agents market size is expected to reach over USD 144.8 billion by 2026 according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 3.4% during the forecast period. Rising prevalence of infectious diseases such as HIV, H1N1, and Ebola virus reflect the profound changes in behavioral patterns of communities over the recent decades. The societal changes and increasing awareness among healthcare professionals and patients are driving the growth.

Organizations, such as the World Health Organization (WHO) and Centers for Disease control and Prevention (CDC) are actively involved in spreading awareness amongst people regarding the fatal implications of infectious diseases and the importance of early treatment. The CDC has collaborated with the National Health Ministry (NHM) in an attempt to spread awareness and to enhance the treatment of communicable diseases in developing countries such as Brazil, China, Nigeria, and India.

However, introduction of novel therapeutics with increased potency and efficacy and the commercialization of pipeline products, such as commercialization of Omadacycline in 2018 for the treatment of Community Acquired Bacterial Pneumonia (CABP), are expected to propel the growth of the anti-infective agents market.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/anti-infective-agents-market

Further key findings from the report suggest:

Antiviral was estimated to be the largest segment with a market share of 48.8% in 2018 owing to the high price associated with the new potent anti-viral drugs, such as Vicriviroc for the treatment of HIV
Antibacterial segment is anticipated to register the fastest CAGR of 4.0% during the forecast period, as antibacterial is the first line of treatment for a large range of infections. Increased prescription and accessibility of antibacterial due to their over-the-counter status is anticipated to further drive the segment
Development of combination drugs to treat and prevent serious and life-threatening infections is expected to propel the usage of anti-infective drugs. For instance, in 2012, Gilead Sciences, Inc. launched Stribild, a comprehensive treatment regimen inclusive of four drugs (cobicistat, elvitegravir, emtricitabine, and tenofovir disoproxil fumarate) used for the treatment of HIV patients without prior retroviral treatment record
Oral route of administration was estimated to be the largest segment in 2018 owing to new product development and presence of strong product pipeline
Hospital pharmacy led the anti-infective agents market in 2018 while e-commerce is expected to be the fastest growing segment during the forecast period
North America was one of the leading regions in terms of revenue in 2018. High prevalence of infectious diseases including hospital-acquired infections in both, children and adults, and the resultant overuse of antibiotics coupled with increased accessibility of non-prescription anti-infectives are the major drivers
Asia Pacific is one of the fastest growing regional segments owing to the presence of high, unmet demand for novel drugs, rapid improvements in healthcare infrastructure coupled with rising awareness among healthcare professionals and patients
Some of the major companies operating in this market are Abbott; Gilead Sciences, Inc.; Bristol-Myers Squibb Company; Merck & Co., Inc.; Bayer AG; AstraZeneca; Boehringer Ingelheim; and Novartis AG.
Effective disease management involves a range of long-term strategies such as new product development, mergers and acquisitions, co-development, and business expansions. For instance, in 2015, ReViral received funding of USD 21 million for the development of its RV521 drug by the Wellcome Trust.

Flow Chemistry Market Size Worth $2.39 Billion By 2025

The global flow chemistry market size is projected to be valued at USD 2.39 billion by 2025, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 10.0% during the forecast period. Lower operating costs of the technology coupled with eco-friendliness is projected to boost the growth.

Substantial reduction in waste generation along with elimination of non-renewable production methods are priorities from a global environment standpoint. Major economies are therefore introducing regulations with a view to minimize the damage to the environment. Numerous governments are introducing measures to achieve the targets set by the Paris Agreement under the United Nations Framework Convention on Climate Changes (UNFCCC), specifically to mitigate the emission of greenhouse gases.

Continuous Stirred Tank (CST) and Plug Flow (PF) are the most commonly adopted reactors in the flow chemistry market. CST reactor systems require limited human intervention to function thereby incurring low labor costs associated with its adoption. Additionally, both reactor technologies have a high output rate, resulting in low production costs.

Increasing adoption of microreactors in specialty chemical, fine chemical, and pharmaceutical manufacturing sectors has contributed substantially to controlling environment damage along with saving manufacturing costs. In the bulk chemicals manufacturing industry, microreactors are used to manufacture styrene, formaldehyde, Ethylene Oxide (EO), and Vinyl Acetate Monomer (VAM) among others.

Pharmaceutical industry is expected to witness maximum growth over the forecast period owing to the ease of continuous separation and crystallization technique offered by flow chemistry technology. Growing need for production cost control coupled with increasing competition in the Active Pharmaceutical Ingredients (API) manufacturing industry is projected to contribute significantly to the demand over the forecast period.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/flow-chemistry-market

Further key findings from the report suggest:

Academia and research application held a market share of 12.45% in 2018 owing to growing use of renewable technologies for manufacturing along with affordable cost of flow chemistry
Asia Pacific is expected to witness the highest CAGR of 11.3% owing to growing adoption of affordable, energy saving, renewable technologies along with substantial investment from petrochemical industry
Microreactor is expected to register an astounding CAGR of 21.0% over the forecast period, due to the demand from pharmaceutical manufacturers owing to better selectivity, affordable production costs, and low waste generation by the product
Notable players operating in the flow chemistry market include Am Technology, CEM Corp., Biotage AB, Syrris Ltd, and Vapourtec Ltd. among others. Companies are strategizing to enhance their geographic presence by making in-roads in Asia Pacific, which is expected to have substantial potential.

Allergy Diagnostics & Therapeutics Market Worth $51.95 Billion By 2026

The global allergy diagnostics and therapeutics market size is expected to reach USD 51.95 billion by 2026 registering a CAGR of 6.3%, according to a new study by Grand View Research, Inc. Increasing prevalence of allergic conditions coupled with adoption of immunoassay as diagnostic test is expected to serve this market with lucrative growth opportunities. According to the report published by the World Allergy Journal in May 2014, around 300 million cases of asthma and 200 to 250 million cases of food allergies were reported. This number is expected to increase over the forecast period due to sedentary lifestyle and poor dietary habits.

cropped view of doctor in white coat and latex gloves holding marker pen near marked female hand

Rising industrial pollution, rapid urbanization in developing countries, and increasing Greenhouse Gas (GHG) concentrations are expected to result in increased prevalence of pollen induced respiratory disorder, thereby boosting the overall market growth over the forecast period. Emergence of technologically advanced products, such as MeDALL allergen-chip for allergy determination, is further expected to propel the market growth in the years to come.

The global market is highly competitive and is led by companies including Thermo Fisher Scientific, Omega Diagnostics, Siemens Healthcare, Stallergenes Greer, Lincoln Diagnostics, bioMerieux, HOB Biotech Group, Alcon Laboratories, Hycor Biomedical, and Hitachi Chemical Diagnostics. Most of the industry participants focus on the development of advanced products and technologies to gain competitive advantage. For instance, in March 2015, Stallergenes received approval for STG 320 in Japan, which is the first sublingual immunotherapy tablet used in the treatment of house dust mite allergy.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/allergy-diagnostic-market

Further key findings from the study suggest:

Instruments product segment is anticipated to witness the highest CAGR of 12.2% from 2019 to 2025 due to high demand for analyzers and laminators for allergy diagnostics
In vitro is expected to be the largest as well as fastest-growing test segment over the estimated period on account of rising demand for minimally invasive and allergen-specific tests
Antihistamines drug class led the allergy diagnostics and therapeutics market in 2018 due to its advantages, such as non sedating nature and minimum side effects with use of second generation antihistamines in allergy treatment
Immunotherapy vaccines is expected to register the maximum CAGR from 2019 to 2025 owing to extensive R&D in the field and advent of sublingual immunotherapy tablets in the treatment of allergic rhinitis
For instance, in April 2014, the U.S. FDA approved a five-grass pollen sublingual tablet (Ex-Oralair) by Stallergenes, which is used in the treatment of pollen allergy